Fig. 4From: Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA reviewNo trend in placebo decline over enrollment time (Study 301 and 302). Trends in placebo group mean changes by enrollment cohorts in Studies 301 and 302Back to article page